Business
Nyxoah Reports Second Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the s
About this update from Nyxoah Sa
[{"type":"image","alt":"Nyxoah","displaySize":"","headline":null,"caption":"Nyxoah","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/e7e3b117995786ca545ccd418ff4f6d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tAkvChng_2zCp_EwJSkW7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e7e3b117995786ca545ccd418ff4f6d2","width":300,"height":103}},"lazy":false},{"type":"text","content":"REGULATED INFORMATION","length":21,"tagName":"p"},{"type":"text","content":"Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch","length":138,"tagName":"p"},{"type":"text","content":"Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025.","length":362,"tagName":"p"},{"type":"text","content":"Recent Financial and Operating Highlights ","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the U.S.","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Kicked off the U.S. commercial launch of the Genio system","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"DREAM pivotal study data published in the Journal of Clinical Sleep Medicine","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue for the second quarter of 2025 was €1.3 million, compared to €0.8 million in the second quarter of 2024, representing 74% year over year growth","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, compared to €63.0 million at the end of March 31, 2025. ","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":603,"olType":false},{"type":"text","content":""This FDA approval represents a historic milestone for N...